Gilteritinib
![]() |
- ₹0
- Product name: Gilteritinib
- CAS: 1254053-43-4
- MF: C29H44N8O3
- MW: 552.71
- EINECS:
- MDL Number:MFCD28144685
- Synonyms:ASP-2215;2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-;6-Ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide;6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide;Gilteritinib (ASP2215);6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydr;ASP2215(Gilteritinib);Gilteritinib(free base)
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :>157°C (dec.)
Boiling point :696.9±55.0 °C(Predicted)
Density :1.242±0.06 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO (25 mg/ml)
form :solid
pka :14.39±0.50(Predicted)
color :Off-white to pale pink
Stability :Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
Boiling point :696.9±55.0 °C(Predicted)
Density :1.242±0.06 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO (25 mg/ml)
form :solid
pka :14.39±0.50(Predicted)
color :Off-white to pale pink
Stability :Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Gilteritinib is an inhibitor of FMS-related tyrosine kinase 3 (FLT3; IC50 = 5 nM for the wild-type enzyme). It inhibits mutant forms of FLT3, including FLT3 with the internal tandem duplication mutation (FLT3-ITD), FLT3-ITD expressing the F691L mutation, and FLT3 with various tyrosine kinase domain mutations (FLT3-TKD; IC50s =1.4-1.8, 12.2, and 0.7-2 nM, respectively). Gilteritinib also inhibits Axl and c-Kit with IC50 values of 41 and 102 nM, respectively. It decreases the viability of blast cells isolated from patients with relapsed acute myeloid leukemia (AML) in a concentration-dependent manner. Formulations containing gilteritinib have been used in the treatment of AML.Related product price
- Dequalinium chloride
₹11745.13